Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report

Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mado, Hubert, Kubicka-Bączyk, Katarzyna, Adamczyk-Sowa, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451259/
https://www.ncbi.nlm.nih.gov/pubmed/34528472
http://dx.doi.org/10.1177/03000605211044378
_version_ 1784569805069615104
author Mado, Hubert
Kubicka-Bączyk, Katarzyna
Adamczyk-Sowa, Monika
author_facet Mado, Hubert
Kubicka-Bączyk, Katarzyna
Adamczyk-Sowa, Monika
author_sort Mado, Hubert
collection PubMed
description Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies.
format Online
Article
Text
id pubmed-8451259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84512592021-09-21 Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report Mado, Hubert Kubicka-Bączyk, Katarzyna Adamczyk-Sowa, Monika J Int Med Res Case Reports Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies. SAGE Publications 2021-09-16 /pmc/articles/PMC8451259/ /pubmed/34528472 http://dx.doi.org/10.1177/03000605211044378 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Reports
Mado, Hubert
Kubicka-Bączyk, Katarzyna
Adamczyk-Sowa, Monika
Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title_full Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title_fullStr Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title_full_unstemmed Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title_short Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
title_sort anti-severe acute respiratory syndrome coronavirus-2 antibody responses following pfizer-biontech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451259/
https://www.ncbi.nlm.nih.gov/pubmed/34528472
http://dx.doi.org/10.1177/03000605211044378
work_keys_str_mv AT madohubert antisevereacuterespiratorysyndromecoronavirus2antibodyresponsesfollowingpfizerbiontechvaccinationinapatientwithmultiplesclerosistreatedwithocrelizumabacasereport
AT kubickabaczykkatarzyna antisevereacuterespiratorysyndromecoronavirus2antibodyresponsesfollowingpfizerbiontechvaccinationinapatientwithmultiplesclerosistreatedwithocrelizumabacasereport
AT adamczyksowamonika antisevereacuterespiratorysyndromecoronavirus2antibodyresponsesfollowingpfizerbiontechvaccinationinapatientwithmultiplesclerosistreatedwithocrelizumabacasereport

Ejemplares similares